Detection of PIK3CA Mutations in Breast Cancer Bone Metastases

Table 1

PIK3CA mutations in bone metastasis samples.

Case	Bone marrow; aspirate	𝑃𝐼𝐾3𝐶𝐴; status	Bone marrow; trephine biopsy	𝑃𝐼𝐾3𝐶𝐴; status	CT-guided bone; metastasis biopsy	𝑃𝐼𝐾3𝐶𝐴; status	Primary; tumour	𝑃𝐼𝐾3𝐶𝐴; status
1	neg.	nd	neg.	nd	neg.	nd	no	nd
2	pos.	E545K	pos.	E545K	pos.	E545K	yes	E545K
3	neg.	nd	pos.	WT	pos.	WT	yes	WT
4	neg.	nd	pos.	H1047R	nd	nd	yes	H1047R
5	nd	nd	neg.	nd	neg.	nd	no	nd
6	neg.	nd	neg.	nd	nd	nd	no	nd
7	neg.	nd	neg.	nd	neg.	nd	no	nd
8	neg.	nd	neg.	nd	neg.	nd	no	nd
9	neg.	nd	neg.	nd	neg.	nd	no	nd
10	neg.	nd	neg.	nd	nd	nd	no	nd
11	neg.	nd	pos.	WT	nd	nd	no	nd
12	neg.	nd	nd	nd	pos.	H1047R hom.	no	nd
13	pos.	WT	pos	WT	pos.	neg.	yes	WT
14	neg.	nd	neg.	nd	nd	nd	no	nd

For aspirate, trephine biopsy and CT-guided biopsy, negative (neg.) or positive (pos.), indicate whether or not tumour cells were present in the biopsy. “nd” indicates when a biopsy procedure or an assay was not performed. WT indicates wild-type 𝑃𝐼𝐾3𝐶𝐴 sequence at hotspot mutation sites; H1047R and E545K indicate mutations. H1047R hom. indicates that this mutation appeared to be homozygous in this patient (all other mutations were heterozygous).